Sharma et al. 2026: From Monotherapy to Sequential Models—Updated Ibogaine Psychiatry Scoping Review

Definition box

Definition: Pravesh Sharma, Jared Kendrick, Jennifer Schram, Sam M. Stumo, Averi Garscia, and Douglas B. Matthews (2026) published *From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders* in *Journal of Psychopharmacology* (doi: 10.1177/02698811261443674; *J Psychopharmacol* 40(7):1103–1117). Searching human studies of ibogaine, noribogaine, or 5-MeO-DMT with clinical outcomes—and prioritizing RCTs, microdosing paradigms, and sequential protocols—they identify only three RCTs. Microdosing and escalating sequential protocols remain experimental, lack standardized definitions, and rest on preliminary observational data. Adverse effects include neurologic, psychiatric, and cardiac events (QTc prolongation); fatalities have occurred with medical/substance comorbidities. Authors conclude evidence is confined to case reports, observational analyses, and small early-phase/proof-of-concept studies; given cardiotoxicity and a narrow therapeutic margin, clinical use cannot be recommended without larger well-controlled trials. This scoping review is not a cure claim and not psychoactive IV ibogaine infusion proof. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (58 words)

Sharma and colleagues’ 2026 Journal of Psychopharmacology scoping review finds only three RCTs on ibogaine/noribogaine pathways, calls sequential dosing experimental, and—citing cardiotoxicity—does not recommend clinical use pending larger controlled trials. That is not proof of psychoactive IV ibogaine infusion and not a cure. Schedule I; prioritize QTc screening.

Why this paper-spoke exists

“Sequential,” “booster,” “microdose,” and “saturation” language spreads faster than RCTs. This review is the clinician-facing brake pedal: limited RCTs, experimental sequential models, cardiotoxicity. Soft CTA: /safety-and-screening → /apply. Pair with Molecules 2026 SUD/cardiac scoping (/blog/scoping-review-ibogaine-sud-cardiac-2026), Glue healthy + patient noribogaine spokes (/blog/glue-2015-noribogaine-healthy-volunteers, /blog/glue-2016-noribogaine-phase1), and trial landscape (/blog/not-losing-momentum-ibogaine-trials-2025).

What was reviewed

| Feature | Accurate description | |---------|----------------------| | Citation | Sharma P. et al. From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders. *J Psychopharmacol*. 2026;40(7):1103–1117. doi 10.1177/02698811261443674 | | Type | Updated scoping review | | Scope | Human studies: ibogaine, noribogaine, or 5-MeO-DMT with clinical outcomes | | Priority lenses | RCTs; microdosing; sequential protocols | | RCTs identified | Three | | Author clinical stance | Clinical use not recommended without larger controlled confirmation given cardiotoxicity/narrow margin | | What it is not | Endorsement of sequential flood marketing; IV brand efficacy proof |

The three RCTs (as summarized by Sharma et al.)

| RCT theme (per review) | Plain-language takeaway | |-------------------------|-------------------------| | Double-blind pilot, n=20 cocaine-dependent adults, single 1800 mg ibogaine vs placebo | Reduced craving signal vs placebo over follow-up up to 24 weeks—in a small pilot | | Ascending-dose noribogaine 3–60 mg in 36 healthy volunteers | Safe/well tolerated in that healthy cohort; no mu-opioid agonist effects (Glue 2015 lineage) | | Randomized study, n=27 opioid-dependent, noribogaine 60–180 mg | Dose-dependent QTc prolongation; withdrawal reductions non-significant (Glue 2016 lineage) |

Two RCTs enrolled substance-dependent populations; one was healthy-volunteer safety/PK. That is a thin randomized spine for a loud internet treatment culture.

Sequential / microdosing models — experimental label

Authors report that microdosing and escalating sequential protocols:

• Remain experimental
• Lack standardized definitions
• Are supported only by preliminary observational data

Family translation: A clinic’s “day 2 booster” storyboard is not the same evidence class as a multi-center Phase 3 program. Do not confuse protocol creativity with regulatory validation.

Cardiac / YMYL emphasis

The review’s adverse-effect catalog explicitly includes QTc prolongation and notes fatalities in the presence of medical and substance-use comorbidities. That aligns with:

• Knuijver clinical QTc work (/blog/knuijver-2021-ibogaine-qtc-safety)
• hERG mechanism papers (/blog/alper-herg-ibogaine-cardiac-mechanism)
• AE systematic review (/blog/ona-2022-ibogaine-adverse-events-review)
• Setting-factor safety review (/blog/ibogaine-setting-factors-safety-review-2023)

Practical gate: /safety-and-screening plus ECG/telemetry literacy (/blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring).

Methods (plain language)

Database search for human clinical-outcome studies, with intentional prioritization of the evidence types clinicians ask about when patients bring printouts: RCTs, microdosing, sequential regimens. Scoping design explains “what exists and how weak/strong it is,” not “here is your guaranteed remission rate.”

Key conclusions (no hype)

• Preliminary interest in neuropsychiatric and SUD applications is accumulating—but evidence quality remains early.
• Only three RCTs meet the authors’ identified set—insufficient for broad clinical recommendation.
• Sequential/microdose paradigms are not standardized ready-to-deploy therapies.
• Neurologic, psychiatric, and cardiac harms—including QTc issues and deaths in comorbid contexts—are part of counseling.
• Clinical use cannot be recommended without confirmation from larger, well-controlled trials.

Honest reading: This is one of the clearest peer-reviewed “not yet” statements in the 2026 psychiatry literature—preserve it against cure marketing.

Route honesty

Reviewed human evidence is dominated by oral/clinic and metabolite Phase 1 traditions—not a psychoactive IV ibogaine infusion brand RCT. Sequential oral storytelling still ≠ IV proof (/blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Scoping of sparse RCTs | Cannot invent Phase 3 certainty | | Observational sequential data | Confounding, expectancy, variable definitions | | Inclusion of 5-MeO-DMT in search lens | Do not conflate molecules when reading secondary blogs | | Author “not recommended” stance | Clinical caution—not anti-research nihilism | | Schedule I context | Off-label enthusiasm ≠ legal U.S. consumer access |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Sequential models are proven standard of care” | False | | “Three RCTs = settled psychiatry indication” | False | | “Review recommends clinical use now” | False — opposite thrust | | “Proves psychoactive IV brand efficacy” | False | | Cite as updated 2026 caution on limited RCTs + cardiotoxicity? | Yes |

No cure claims.

Soft CTA

If someone sold you a multi-day sequential storyboard as “the new science,” compare it to Sharma et al.’s actual conclusions. Then start at /safety-and-screening and /apply only with physician-supervised IV ibogaine infusion questions and cardiac eyes open. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Sharma 2026 paper? An updated *J Psychopharmacol* scoping review on ibogaine in psychiatric treatment, emphasizing monotherapy vs sequential models (doi **10.1177/02698811261443674**).

How many RCTs did they find? **Three**—a thin randomized evidence base.

Are sequential dosing protocols proven? No—authors call them experimental and non-standardized.

Do the authors recommend clinical use today? No—not without larger well-controlled trials, given cardiotoxicity and narrow therapeutic margin.

Does this prove IV ibogaine infusion works? No.

Is QTc risk mentioned? Yes—QTc prolongation and cardiac adverse events are explicit.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Sharma et al. 2026 is a scoping review that does not recommend clinical use pending larger trials—not personal access, not a cure claim, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Sharma P., Kendrick J., Schram J., Stumo S.M., Garscia A., Matthews D.B. From monotherapy to sequential models… *J Psychopharmacol*. 2026;40(7):1103–1117. doi: 10.1177/02698811261443674.
2. Glue P. et al. *J Clin Pharmacol*. 2015. doi: 10.1002/jcph.404.
3. Glue P. et al. *Clin Pharmacol Drug Dev*. 2016. doi: 10.1002/cpdd.254.
4. Esperança M.P. et al. *Molecules*. 2026. doi: 10.3390/molecules31030545.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).